379 related articles for article (PubMed ID: 24505831)
1. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
2. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
Kelly C
Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
[TBL] [Abstract][Full Text] [Related]
3. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
4. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
5. Recent trends in brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R
J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
[TBL] [Abstract][Full Text] [Related]
6. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
7. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
8. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
9. Updated trends in US brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R; Boyo A
J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
[TBL] [Abstract][Full Text] [Related]
10. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
Tang WL
Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
[TBL] [Abstract][Full Text] [Related]
11. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
12. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
13. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
14. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
15. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
16. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
17. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
Brockmeier MS
Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
[No Abstract] [Full Text] [Related]
18. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
19. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
20. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
Grabowski HG; Kyle M; Mortimer R; Long G; Kirson N
Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]